Cardiogenetics

Devyser Thrombophilia

Discover the advantages

- One single mix allows testing of six relevant risk factors for thrombophilia
- Speed and ease of use: single tube PCR minimizes hands-on time
- Accurate and efficient: single tube PCR reduces analysis times while minimizing the risk of sample mix-up

Genetic risk factors for thrombophilia

Thrombophilia is an abnormality of blood coagulation, leading to an increased risk of thrombosis. Thrombophilia can be identified in 50% of people who have an episode of thrombosis that was not provoked by other causes. Venous thrombosis is one of the most common thrombotic disorders affecting up to 2 in 1,000 individuals every year and is associated with life-threatening conditions such as pulmonary embolism.

The predisposition to form blood clots can arise from mutations, acquired changes in the clotting mechanism or, more commonly, an interaction between genetic and acquired factors. The risk of thrombosis increases with the number of genetic and acquired risk factors present so that individuals with multiple risk factors are at greater risk than those with just a few.

Effective detection with Devyser Thrombophilia

The Devyser Thrombophilia assay offers a very simple procedure for testing the most relevant mutations implicated in the risk of developing thrombophilia and venous thromboembolism (VTE). It is a multiplex PCR reagent kit for simultaneous detection of six genetic risk factors associated with thrombophilia:

- *Factor V Leiden, G1691A/R506Q:* One of the most important genetic risk factors for inherited thrombophilia, occurs in 20-50% of patients with VTE.
- *Factor V R2 (H1299R):* Compound heterozygosity for FV R2 and FV Leiden is associated with an increased risk for venous thrombosis compared to that seen in FV Leiden heterozygotes alone.
- *Prothrombin/Factor II (G20210A):* Carriers have elevated risk for thrombosis; significantly increased risk in combination with FV Leiden.
- *5,10-Methylenetetrahydrofolate Reductase (MTHFR),C677T:* Homozygosity predisposes to thrombosis in the presence of additional risk factors.
- *MTHFR, A1298C:* Compound heterozygosity for MTHFR C677T and MTHFR A1298C is considered a risk factor for cardiovascular disease.
- *Plasminogen Activator Inhibitor 1 (PAI-1/ SERPINE1) 4G/5G:* the 4G allele is considered to be a mild risk factor for VTE and Myocardial Infarction.

Technical specifications

Intended use:
The Devyser Thrombophilia kit is an in vitro diagnostic product for qualitative detection of genetic variants that may be associated with thrombophilia.

Parameters tested:
Factor V Leiden, Factor V R2, Prothrombin/Factor II, MTHFR C677T, MTHFR A1298C, PAI-1/ SERPINE1 4G/5G
CE- labelled for IVD use

Detection format:
Thermo Fisher's capillary electrophoresis instruments: ABI 310, ABI 3130, ABI 3500, ABI 3730

Ready to use for PCR

Kit size:
48 tests

Article number:
8-A035

Accessories:
DNA Size marker 560 SIZER ORANGE (Art. No.: 8-A402)

Contact

Instrumentvägen 19
SE-12653 Hägersten
Sweden
Tel: +46-(0)8-562 158 50
Fax: +46-(0)8-32 64 88
Web: www.devyser.com
Email: info@devyser.com

Devyser. Results for life.

Devyser is specialized in the development, manufacture and sales of diagnostic kits for complex DNA testing within Oncology, Reproductive Health and Hereditary Diseases. The products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics as well as in a wide array of genetic tests. Devyser's product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results.

DEVYSER
RESULTS FOR LIFE